Neurocrine Biosciences (NBIX) stock chart: the past year in 6 moments

• Target raisedNov 4, 2026
  Guggenheim

  Buy · PT $207.00 → $224.00
• Target raisedNov 3, 2026
  Piper Sandler

  Overweight · PT $210.00 → $215.00
• Target raisedNov 3, 2026
  Canaccord Genuity

  Buy · PT $210.00 → $220.00
• Target raisedNov 3, 2026
  RBC Capital

  Outperform · PT $187.00 → $190.00
• Target raisedNov 3, 2026
  Morgan Stanley

  Equal-Weight · PT $183.00 → $185.00
• Target cutOct 12, 2026
  BMO Capital

  Market Perform · PT $164.00 → $150.00
• InitiationOct 6, 2026
  Guggenheim

  Buy · PT $207.00
• Target cutSep 29, 2026
  UBS

  Buy · PT $231.00 → $214.00
• Target raisedSep 11, 2026
  Morgan Stanley

  Equal-Weight · PT $182.00 → $183.00
• Target raisedSep 3, 2026
  Citigroup

  Buy · PT $249.00 → $253.00
• Target cutAug 13, 2026
  Morgan Stanley

  Equal-Weight · PT $196.00 → $182.00
• Target raisedAug 3, 2026
  Canaccord Genuity

  Buy · PT $200.00 → $210.00
• Target raisedJul 31, 2026
  Citigroup

  Buy · PT $246.00 → $249.00
• Target raisedAug 3, 2026
  Wedbush

  Outperform · PT $185.00 → $194.00
• Target raisedAug 3, 2026
  Truist Securities

  Buy · PT $200.00 → $213.00
• Target raisedJul 31, 2026
  Needham

  Buy · PT $200.00 → $204.00
• Target raisedJul 31, 2026
  Stifel

  Buy · PT $188.00 → $215.00
• Target raisedJul 31, 2026
  Guggenheim

  Buy · PT $200.00 → $222.00
• Target raisedJul 31, 2026
  Cantor Fitzgerald

  Overweight · PT $210.00 → $215.00
• Target raisedJul 31, 2026
  Piper Sandler

  Overweight · PT $207.00 → $210.00
• Target raisedJul 31, 2026
  TD Cowen

  Buy · PT $200.00 → $220.00
• Target raisedJul 31, 2026
  Morgan Stanley

  Equal-Weight · PT $193.00 → $196.00
• Target raisedJul 31, 2026
  RBC Capital

  Outperform · PT $195.00 → $198.00
• Target raisedJul 21, 2026
  Guggenheim

  Buy · PT $175.00 → $200.00
• Target raisedJul 17, 2026
  Wells Fargo

  Overweight · PT $175.00 → $200.00
• Target raisedJul 13, 2026
  BMO Capital

  Market Perform · PT $144.00 → $170.00
• Target raisedJul 13, 2026
  Truist Securities

  Buy · PT $155.00 → $200.00
• Target raisedJul 7, 2026
  RBC Capital

  Outperform · PT $183.00 → $195.00
• Target raisedJun 30, 2026
  UBS

  Buy · PT $182.00 → $208.00
• InitiationJun 2, 2026
  Goldman Sachs

  Buy · PT $213.00
• Target raisedMay 29, 2026
  RBC Capital

  Outperform · PT $180.00 → $183.00
• InitiationMay 22, 2026
  Bernstein

  Outperform · PT $221.00
• Target raisedMay 8, 2026
  JP Morgan

  Overweight · PT $177.00 → $185.00
• Target raisedMay 7, 2026
  Truist Securities

  Buy · PT $140.00 → $155.00
• Target raisedMay 6, 2026
  Wedbush

  Outperform · PT $166.00 → $176.00
• Target raisedMay 6, 2026
  Piper Sandler

  Overweight · PT $190.00 → $207.00
• Target raisedMay 6, 2026
  RBC Capital

  Outperform · PT $176.00 → $180.00
• Target raisedMay 6, 2026
  Morgan Stanley

  Equal-Weight · PT $185.00 → $191.00
• Target raisedMay 6, 2026
  Citigroup

  Buy · PT $242.00 → $246.00
• Target raisedApr 22, 2026
  Leerink Partners

  Outperform · PT $160.00 → $170.00
• Target raisedApr 10, 2026
  Morgan Stanley

  Equal-Weight · PT $173.00 → $185.00
• Target raisedApr 7, 2026
  HC Wainwright & Co.

  Buy · PT $192.00 → $215.00
• Target raisedApr 7, 2026
  Wedbush

  Outperform · PT $151.00 → $166.00
• Target raisedApr 7, 2026
  Canaccord Genuity

  Buy · PT $164.00 → $200.00
• Target raisedApr 7, 2026
  Citigroup

  Buy · PT $204.00 → $242.00
• Target raisedMar 12, 2026
  JP Morgan

  Overweight · PT $176.00 → $177.00
• InitiationFeb 24, 2026
  Wolfe Research

  Outperform · PT $160.00
• Target cutFeb 17, 2026
  Truist Securities

  Buy · PT $169.00 → $140.00
• Target cutFeb 17, 2026
  JP Morgan

  Overweight · PT $177.00 → $176.00
• Target cutFeb 13, 2026
  Wells Fargo

  Overweight · PT $180.00 → $175.00
• Target cutFeb 12, 2026
  Needham

  Buy · PT $187.00 → $185.00
• Target cutFeb 12, 2026
  HC Wainwright & Co.

  Buy · PT $198.00 → $192.00
• Target raisedFeb 12, 2026
  Wedbush

  Outperform · PT $149.00 → $151.00
• Target cutFeb 12, 2026
  BMO Capital

  Market Perform · PT $147.00 → $140.00
• Target cutFeb 12, 2026
  RBC Capital

  Outperform · PT $180.00 → $177.00
• Target raisedFeb 12, 2026
  Citigroup

  Buy · PT $203.00 → $204.00
• Target cutJan 23, 2026
  UBS

  Buy · PT $188.00 → $178.00
• Target cutJan 12, 2026
  JP Morgan

  Overweight · PT $179.00 → $177.00
• DowngradeJan 8, 2026
  Morgan Stanley

  Overweight → Equal-Weight · PT $173.00 → $175.00
• Target cutJan 8, 2026
  Truist Securities

  Buy · PT $172.00 → $169.00
• Target raisedDec 17, 2025
  HC Wainwright & Co.

  Buy · PT $168.00 → $198.00
• Target raisedDec 12, 2025
  Mizuho

  Neutral · PT $146.00 → $175.00
• Target raisedDec 11, 2025
  Stifel

  Buy · PT $183.00 → $188.00
• Target raisedDec 8, 2025
  RBC Capital

  Outperform · PT $160.00 → $180.00
• Target raisedDec 5, 2025
  TD Cowen

  Buy · PT $175.00 → $200.00

Nothing in the past 12 months.

• NewsNov 5, 2026
  Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules
• NewsNov 4, 2026
  Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224
• Why it's movingNov 3, 2026
  Neurocrine shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 INGREZZA net product sales guidance. Also, Canaccord and Piper Sandler raised their respective price targets.
• NewsOct 26, 2026
  Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients
• NewsOct 22, 2026
  Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition
• Why it's movingOct 20, 2026
  Neurocrine Biosciences shares are trading higher after the company announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer's disease.
• NewsOct 16, 2026
  Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026
• NewsOct 12, 2026
  BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150
• NewsOct 6, 2026
  Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207
• NewsSep 29, 2026
  UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214
• NewsSep 11, 2026
  Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183
• NewsSep 8, 2026
  RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target
• NewsSep 3, 2026
  Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
• NewsAug 26, 2026
  Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
• NewsAug 13, 2026
  Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182
• NewsAug 12, 2026
  What's Going On With Neurocrine Biosciences Stock On Wednesday?
• NewsAug 7, 2026
  Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity
• NewsAug 3, 2026
  Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210
• NewsAug 3, 2026
  Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213
• Why it's movingJul 31, 2026
  Neurocrine Biosciences shares are trading lower after the company reported Q2 financial results, and may be falling amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction. The stock previously collaborated with Transthera for NLRP3 inhibitors.
• NewsJul 21, 2026
  Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200
• NewsJul 17, 2026
  Wells Fargo Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $200
• NewsJul 13, 2026
  Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200
• NewsJul 7, 2026
  RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $195
• NewsJul 1, 2026
  Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Congenital Adrenal Hyperplasia
• NewsJun 15, 2026
  Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWS
• NewsJun 15, 2026
  Neurocrine Biosciences Presents New Two-Year Data From Phase 3 CAHtalyst Pediatric Trial Of CRENESSITY At Endocrine Society's Annual Meeting
• NewsJun 8, 2026
  Neurocrine Biosciences Reports Rapid Tardive Dyskinesia Improvement With INGREZZA In Patients With Intellectual And Developmental Disabilities
• NewsJun 4, 2026
  Watching Neurocrine Biosciences; Hearing Investor Business Daily SwingTrader Buys Stock
• Why it's movingJun 3, 2026
  Neurocrine Biosciences shares are trading higher. The company announced it will present multiple new analyses of key clinical and patient-reported outcomes up to two years of treatment with CRENESSITY at ENDO 2026.
• NewsJun 2, 2026
  Goldman Sachs Reinstates Buy on Neurocrine Biosciences, Announces $213 Price Target
• NewsMay 29, 2026
  RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $183
• NewsMay 22, 2026
  Bernstein Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $221
• NewsMay 18, 2026
  Neurocrine Biosciences Presents New Data From Clinician Survey Highlighting Functional Impact Experienced By Patients With Mild TD Severity And Impact Of Treatment With INGREZZA Capsules In Real-World Setting
• NewsMay 8, 2026
  JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $185
• NewsMay 7, 2026
  Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $155
• Why it's movingMay 6, 2026
  Neurocrine Bioscience shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Wedbush maintained an Outperform rating on the stock and raised its price target from $166 to $176.
• NewsMay 4, 2026
  Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating Safety And Tolerability Of NBIP-'2118 In Adult Participants
• NewsApr 29, 2026
  Neurocrine Biosciences Announces Publication Of New Peer-Reviewed Research In The Journal Of Clinical Psychiatry Characterizing Patient-Reported Improvement With INGREZZA Capsules Across KINECT Clinical Program
• NewsApr 22, 2026
  Neurocrine Biosciences Presents New 2-Yr Data From Phase 3 CAHtalyst Adult Study Demonstrating Sustained Reductions In GC Doses In Adults With Classic Congenital Adrenal Hyperplasia Treated With CRENESSITY
• NewsApr 22, 2026
  Leerink Partners Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $170
• NewsApr 14, 2026
  Neurocrine Biosciences Announces Tardive Dyskinesia Patients Treated With Its INGREZZA Capsules Demonstrated Higher Treatment Persistence Compared To AUSTEDO XR
• NewsApr 7, 2026
  Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $242
• M&AApr 6, 2026
  Soleno Therapeutics (SLNO) was acquired by Neurocrine Biosciences (NBIX) on Monday, May 18, 2026 for $2.9B paid in cash

  Completed · $2.9B
• NewsApr 6, 2026
  Needham Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target
• NewsMar 12, 2026
  JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $177
• NewsFeb 24, 2026
  Wolfe Research Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $160
• NewsFeb 17, 2026
  JP Morgan Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $176
• NewsFeb 13, 2026
  Wells Fargo Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $175
• Why it's movingFeb 12, 2026
  Neurocrine Biosciences shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.